Recipharm is pleased to announce that the results of the study with Erdosteine as an add-on treatment for Covid-19 patients are now available. The clinical study involved 20 patients affected by COVID-19 with severe respiratory failure, hospitalized in one of the major COVID-19 centres of Milan, in Lombardy, the Italian region mostly affected by SARS-CoV-2. […]

The post Recipharm's Proprietary Molecule Erdosteine has been positively tested as part of COVID-19 treatment first appeared on World Pharma Today.